ARTICLE | Clinical News
DNDN starts early-stage prostate cancer trial
June 11, 2001 7:00 AM UTC
Dendreon (DNDN) began double-blind, placebo-controlled U.S. Phase III testing of its Provenge cancer vaccine in patients with early-stage prostate cancer. Provenge, an activated autologous dendritic c...